Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Samantha Du

When Samantha Du left Pfizer in 2001 to take up a drug development job in China, the country's biopharma ecosystem hadn't contributed much to the global drug pipeline since the 1967 discovery of artemisinin. Now, China's burgeoning life sciences sector is basking in venture capital, industry and government interest. Earlier this year, the China Drug Administration (CDA) granted a landmark approval for Chi-Med's fruquintinib, a discovered-and developed-in-China VEGFR inhibitor that Du helped usher towards patients during her time as CSO of Chi-Med. Zai Lab, the company that Du founded in 2014 and that she heads as CEO, is meanwhile setting new precedents by recruiting Chinese patients into global registrational trials. Du spoke with Asher Mullard about the changing Chinese biopharma ecosystem.

This is a preview of subscription content, access via your institution

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Samantha Du. Nat Rev Drug Discov 17, 856–857 (2018). https://doi.org/10.1038/nrd.2018.208

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd.2018.208

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing